Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

EHA-NSHBT Sickle Cell Disease Webinar

EHA and the Topics-in-Focus Taskforce on Hemoglobinopathies are working with the Nigerian Society of Haematology and Blood Transfusion (NSHBT) to organize a webinar on Sickle Cell Disease (SCD).

Read more

YoungEHA Webinar on Burnouts: When caregivers become patients - talking about awareness

In order to create awareness for burnout symptoms among hematologists, the YoungEHA Committee has planned a webinar on burnouts to help professionals in hematology identify early signs and how to address this issue in a wider context.

Read more

A journey to hematology – a dream come true

YoungEHA proudly presents our first blog authored by a guest writer, Dr. Ana Zelić Kerep, a resident physician in the Department of Hematology, University Hospital Center Zagreb, Croatia. A journey to hematology – a dream come true

by Dr.

Read more

Rolling out CAR T across Europe

Prof Christine Chomienne talking about CAR T implementation challenges during the 7th EAPM Presidency Conference in Brussels.

Read more

1st EHA-Balkan Hematology Day

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 1st edition of the EHA-Balkan Hematology Day.

Read more

Meet Irene Roberts, our September volunteer of the month

Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.

Read more